Un CharacterizED B Molecule Interaction Domain-containing 1: Potential Drug Target

Target Name: UBIAD1

NCBI ID: G29914

UBIAD1

Un CharacterizED B Molecule Interaction Domain-containing 1: Potential Drug Target

UBIAD1 (Uncharacterized B molecular interaction domain-containing 1) is a protein that is expressed in various tissues and cells throughout the body. It has been identified as a potential drug target (or biomarker) due to its unique structure and its involvement in various cellular processes.

UBIAD1 is a member of the BID (BID) family, which is a conserved group of proteins that play a critical role in cell signaling. BID proteins are known for their ability to interact with a wide variety of molecules, including small molecules, peptides, and proteins. This interaction is critical for the protein's function and for the regulation of cellular processes.

One of the unique features of UBIAD1 is its ability to interact with small molecules, such as drugs. This interaction is critical for the development of drug resistance and for the regulation of cellular processes that are sensitive to small molecules.

In addition to its potential role in drug resistance, UBIAD1 is also involved in the regulation of cellular processes that are critical for tissue growth and development. It has been shown to play a role in the regulation of cell proliferation, differentiation, and migration.

UBIAD1 is also involved in the regulation of cellular processes that are critical for the development and maintenance of tissues. It has been shown to play a role in the regulation of cell survival and in the development of tissues such as the skin, hair, and nails.

Another unique feature of UBIAD1 is its ability to interact with other proteins. This interaction is critical for the regulation of cellular processes and for the development of tissues.

In addition to its role in the regulation of cellular processes, UBIAD1 is also involved in the development and maintenance of tissues. It has been shown to play a role in the regulation of cell proliferation and in the development of tissues such as the skin, hair , and nails.

Overall, UBIAD1 is a unique protein that is involved in a wide range of cellular processes that are critical for the development and maintenance of tissues. Its interaction with small molecules and its role in the regulation of cellular processes make it an attractive drug target. Further research is needed to fully understand the role of UBIAD1 in the development and maintenance of tissues and to identify potential drugs that can target this protein.

Protein Name: UbiA Prenyltransferase Domain Containing 1

Functions: Prenyltransferase that mediates the formation of menaquinone-4 (MK-4) and coenzyme Q10 (PubMed:20953171, PubMed:23374346). MK-4 is a vitamin K2 isoform present at high concentrations in the brain, kidney and pancreas, and is required for endothelial cell development (PubMed:20953171). Mediates the conversion of phylloquinone (PK) into MK-4, probably by cleaving the side chain of phylloquinone (PK) to release 2-methyl-1,4-naphthoquinone (menadione; K3) and then prenylating it with geranylgeranyl pyrophosphate (GGPP) to form MK-4 (PubMed:20953171). Also plays a role in cardiovascular development independently of MK-4 biosynthesis, by acting as a coenzyme Q10 biosynthetic enzyme: coenzyme Q10, also named ubiquinone, plays an important antioxidant role in the cardiovascular system (PubMed:23374346). Mediates biosynthesis of coenzyme Q10 in the Golgi membrane, leading to protect cardiovascular tissues from NOS3/eNOS-dependent oxidative stress (PubMed:23374346)

The "UBIAD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBIAD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets